Fusion protein based on anti-EGFR single-chain antibody and arginine nonamer, and applications of fusion protein

Abstract

The invention discloses a fusion protein based on anti-EGFR single-chain antibody and arginine nonamer, and applications of the fusion protein. The fusion protein comprises a heavy chain variable region and a light chain variable region which are connected via connection peptides; the terminal of the light chain variable region is connected with the arginine nonamer; and amino acid sequence of the arginine nonamer is represented by SEQ ID No.3. According to the fusion protein, the heavy chain variable region and the light chain variable region of the anti-EGFR single-chain antibody are connected via the selected connection peptides, so that specificity and affinity of combination of the antibody with EGFR are maintained, and targeting performance of the constructed fusion protein on EGFR is ensured; the size of the fusion protein is reduced, so that on the one hand construction, expression and purification of the fusion protein are convenient, and cost is reduced, and on the other hand, combination of the fusion protein on EGFR is ensured, demands on molecular size and antibody activity during cellular internalization are ensured, and feasibility and accuracy of the combination of the fusion protein on EGFR and targeting tumor cellular internalization are ensured.

Description

technical field [0001] The invention belongs to the field of anti-tumor technology, and relates to a fusion protein based on anti-EGFR single-chain antibody and arginine nonamer and its application. Background technique [0002] The epidermal growth factor receptor (EGFR) family is a class of transmembrane protein receptors with tyrosine kinase activity and plays an important role in the occurrence, development and metastasis of tumor cells by regulating downstream signal transduction. EGFR is overexpressed in glial cells, renal cancer, lung cancer, prostate cancer, pancreatic cancer, breast cancer and other tissues. The high expression of EGFR plays a key role in the proliferation, cell cycle, invasion and angiogenesis of some malignant tumor cells (Mendelsohn J, J Clin Oncol, 2003, 21(14):2787-2799), EGFR has become an antitumor drug Or an important target for a vaccine. [0003] EGFR is highly expressed in tumors and plays an important role in tumor growth and different...

AI Technical Summary

Problems solved by technology

However, in the research and development of EGFR inhibitors, although gefitinib and cetuximab have been used clinically, the efficacy is not satisfactory, and some other biological inhibitors are still in the stage of basic research and clinical research

Images